A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma.

Trial Profile

A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs Vorinostat (Primary) ; Bexarotene
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Sep 2009 Actual initiation date changed from Aug 2005 to Sep 2005 as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 May 2009 Actual initiation date changed from Sep 2005 to Aug 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top